Overexpression of HER-2/neu (also known as c-erbB-2) proto-oncogene frequently occurs in many dierent types of human cancers, including ovarian carcinoma, and is known to enhance tumor metastasis and chemoresistance. Previous studies showed that inhibition of HER-2/neu expression by various agents, such as adenovirus E1A and simian virus 40 large T, can lead to suppression of tumorigenicity of HER-2/neu-overexpressing cancer cells. Here we report that T/t-common, which contains the N-terminal common domain of simian virus 40 large T and small t antigens, could speci®cally repress the HER-2/neu promoter. When the coding sequence of T/tcommon was stably transfected into the HER-2/neuoverexpressing human ovarian carcinoma SK-OV-3 cells, the expression of HER-2/neu was dramatically reduced by the expression of T/t-common. Accordingly the tumorigenic potential of these T/t-common-expressing clones, including the ability to grow anchorage-independently and the ability to induce tumor in nu/nu mice, was also drastically suppressed. Furthermore, when T/tcommon was transiently cotransfected with the activated genomic neu into NIH3T3 cells, the transforming activity of the latter was suppressed by T/t-common in soft-agarose microcolony formation assays. Taken together, these data suggest that T/t-common may act as a transformation suppressor of the HER-2/neu oncogene.
Introduction
The HER-2/neu (also known as c-erbB-2) protooncogene encodes a molecular weight of 185 kDa epidermal growth factor receptor-related transmembrane protein with intrinsic tyrosine kinase activity (Coussens et al., 1985; Hung et al., 1986; Yamamoto et al., 1986) . Ampli®cation or overexpression of HER-2/ neu has been detected frequently in many types of human cancers, including cancers of the breast, ovary, lung, kidney, colon, bladder, esophagus, stomach, mouth and salivary gland (reviewed by Hynes and Stern, 1994) . Overexpression of HER-2/neu is correlated with poor prognosis (Slamon et al., 1987 (Slamon et al., , 1989 Berchuck et al., 1990; Hynes and Stern, 1994) , enhanced metastatic potential (Slamon et al., 1987; Yu et al., 1994; Hynes and Stern, 1994) , and increased chemoresistance (Tsai et al., 1993; Hynes and Stern, 1994) of human cancers. Taken together, these data indicate that HER-2/neu is a potent oncogene, and its overexpression plays a crucial role in the development of human malignancies.
Two viral oncoproteins, adenovirus 5 E1A and simian virus 40 (SV40) large T, have been reported to repress transcription from the HER-2/neu promoter and consequently repress the transforming activity of HER-2/neu (Yu et al., 1990 (Yu et al., , 1991 Matin and Hung, 1993; Hung et al., 1995; . When E1A is stably transfected into cells, it can repress HER-2/neu overexpression and suppress the tumorigenic and metastatic potential of activated HER-2/neu-transformed mouse 3T3 cells and dissemination of human ovarian cancer cells that overexpress HER-2/neu (Yu et al., 1991 (Yu et al., , 1992 (Yu et al., , 1993 . Moreover, in mice bearing HER-2/neu-overexpressing ovarian, lung, or breast cancer cells, E1A delivered either by adenovirus or liposome signi®cantly inhibits tumor growth and prolongs mouse survival Zhang et al., 1995; Chang et al., 1996 Chang et al., , 1997 . These results strongly suggest that by repressing HER-2/neu overexpression, it is possible to achieve therapeutic eects on cancers that overexpress HER-2/neu. SV40 small t antigen is one of the two transformation-related proteins encoded by the early region of the virus (reviewed by Tooze, 1981) . While SV40 large T antigen is the primary transforming element of the virus, small t serves as a transformation helper which enhances the transforming activity of large T (Bikel et al., 1987) . The N-terminal 82 amino acids of small t and large T are identical (which is called T/t-common here), while the remaining 92 amino acids of small t are unique. In addition to the transformation enhancing function, small t has been shown to associate with protein phosphatase 2A (Pallas et al., 1990) and inhibit the enzymatic activity of the latter (Yang et al., 1991) . Moreover, small t was shown to be a transcriptional regulator (Loeken et al., 1988; Wang et al., 1994) . It can activate transcription from certain genes, including cyclin A (PorraÂ s et al., 1996) and cyclin D1 (Watanabe et al., 1996) , but repress a variety of promoters in CV-1P cells . Recently, small t was shown to stimulate protein kinase C z activity by interacting with protein phosphatase 2A, resulting in the activation of mitogen-activated protein kinase pathway, cell proliferation and transcriptional activation of the NF-kB-dependent genes (Sontag et al., 1997) .
Ovarian carcinoma is the most lethal tumor of the female genital tract and continues to be the major cause of death of female cancers. Because of the lack of eective screening and therapeutic strategies, the longterm survival rate of ovarian cancer patients is relatively low. Therefore, it is imperative to develop novel means to treat this aggressive and devastating malignancy. Previous studies demonstrated that ampli®cation/overexpression of HER-2/neu is a common phenomenon in primary ovarian cancers across dierent populations (Slamon et al., 1989; Berchuck et al., 1990; Hung et al., 1992) . As stated above, it is possible to treat this particular group of tumors by delivering agents that speci®cally repress HER-2/neu expression into cells. Previously, we reported that the SV40 small t antigen can repress transcription from a variety of promoters and that the T/t-common polypeptide has an even stronger repressing activity than small t . We therefore tested whether small t and T/tcommon, like E1A, could repress HER-2/neu expression. We found that both small t and T/t-common, as expected, repressed the HER-2/neu promoter eectively. Since T/t-common showed a much stronger repressing eect on the HER-2/neu promoter than small t, we used T/t-common for a further study and asked whether it could suppress the tumorigenicity of HER-2/neu-overexpressing ovarian cancer cells. We found that T/tcommon indeed could suppress the transformed phenotypes of the HER-2/neu-overexpressing ovarian carcinoma SK-OV-3 cells, presumably by inhibiting the expression of HER-2/neu in these cells. Together, our data suggest that T/t-common could act as a transformation suppressor of the HER-2/neu oncogene and had the potential to be developed as a therapeutic agent for the treatment of HER-2/neu-overexpressing ovarian cancers.
Results
Repression of the human HER-2/neu promoter by the SV40 small t and T/t-common polypeptides To test whether SV40 small t and T/t-common could repress the HER-2/neu promoter, we performed transient cotransfection assays. At ®rst, we constructed a HER-2/neu promoter-reporter plasmid, pHER498-Luc, which contains a copy of the human HER-2/neu promoter (nucleotide 7498 to +30 relative to the major transcription start site) positioned immediately upstream of the luciferase gene (Figure 1d ). This reporter plasmid was then cotransfected with a small t-expressing (pRSV-t/cDNA), T/t-common-expressing (pRSV-T/t-common), large T-expressing (pRSV-TEX) or control vector (pRSV.3-BglII) plasmid into CV-1P cells. These eector plasmids directed the synthesis of the abundant product, in nearly all equivalent amounts, and of the predicted molecular size in CV-1P cells (Figure 1a) . Cotransfection of either the small t-or T/t-common-expressing plasmid led to a signi®cant decrease of luciferase activity while cotransfection of the large T-expressing plasmid repressed slightly the synthesis of luciferase (Figure 1b) . T/t-common was much more ecient in repressing pHER498-Luc than small t in more than six experiments. Both small t and T/t-common could repress not only the human HER-2/ neu promoter but also the rat neu promoter, because the CAT synthesis driven by pNeuEcoRI-CAT (Yu et al., 1990 ), a reporter which contains 2.2 kb of the rat neu promoter linked to the CAT gene, was also signi®cantly repressed by a small t and T/t-common (data not shown). The repression of the HER-2/neu promoter by T/t-common was also observed in human ovarian carcinoma SK-OV-3 cells in similar cotransfection experiments (Figure 1c) . The inhibitory activity of T/t-common was speci®c to the HER-2/neu promoter, since the activity of the human p21 WAF1 promoter was unaected by a similar amount of T/t-common ( Figure  1c) .
We next mapped the region of the HER-2/neu promoter that responds to T/t-common. To this end, series deletion constructs of the HER-2/neu-promoterluciferase (Figure 1d , upper panel) were cotransfected with the T/t-common-expressing plasmid into CV-1P cells. As shown in Figure 1d , the promoter activity of all the deletion constructs, including pHER81-Luc which contains only 81 bp of HER-2/neu upstream regulatory sequences, was repressed by T/t-common. This result indicates that repression of HER-2/neu by T/t-common is mediated through the promoter region located between 781 and +30 relative to the major transcription start site of the HER-2/neu gene. This result is consistent with the results of Matin and Hung (1993) , which showed that large T inhibited the activity of the minimum promoter of neu. Taken together, the above results demonstrate that both small t and T/t-common can speci®cally inhibit the activity of the HER-2/neu promoter. Since T/tcommon was much more eective than small t in repressing the HER-2/neu promoter, T/t common was used for further analysis.
Expression of HER-2/neu was inhibited in T/t-common-expressing ovarian carcinoma cell lines
The human ovarian carcinoma cell line SK-OV-3 has been shown to overexpress HER-2/neu mRNA at least a 100-fold higher than other cancer cell lines from the female genital tract . The level of HER-2/neu overexpression was shown to correlate with the degree of malignancy in the ovarian carcinoma cells (Yu et al., 1993) . Since T/t-common was able to repress the HER-2/neu promoter, we hypothesized that T/tcommon might be able to suppress the tumorigenicity of the SK-OV-3 cells through repressing HER-2/neu expression. To study the eect of T/t-common on the tumorigenicity of the SK-OV-3 cells, we ®rst generated the T/t-common-expressing and vector-transfected SK-OV-3 cell lines (hereafter referred to as SK-T/t and SK-NEO cell lines, respectively) and then examined the expression of HER-2/neu in these cell lines.
Four T/t-common-expressing SK-OV-3 cell lines (SK-T/t-1, SK-T/t-2, SK-T/t-3 and SK-T/t-4) and two vector-transfected SK-OV-3 cell lines (SK-NEO-1 and SK-NEO-2) were established. All of the four SK-T/t cells lines were con®rmed to produce the T/t-common transcript by a reverse transcription-polymerase chain reaction (data not shown). The synthesis of the T/tcommon polypeptide in these SK-T/t cell lines was analysed by immunoprecipitation of the T/t-common polypeptide using anti-T/t-common monoclonal antibody pAB419. As shown in Figure 2 , all of the four SK-T/t cell lines as well as the CV-1P cells transfected with the T/t-common-expressing plasmid (pRSV-T/tcommon) expressed the T/t-common polypeptide while the parental and vector-transfected SK-OV-3 cell lines as well as the CV-1P cells transfected with the vector plasmid (pRSV.3-BglII) did not do so.
To examine whether expression of T/t-common in SK-T/t cell lines could inhibit HER-2/neu expression, we measured the abundance of HER-2/neu mRNA in Figure 1 (a) Immunoprecipitation of SV40 large T, small t, or T/t-common polypeptide following transfection of CV-1P cells with a large T-(pRSV-TEX), small t-(pRSV-t/cDNA), or T/t-common-expressing (pRSV-T/t-common) plasmid. Twenty micrograms of pRSV-TEX (lane 2), pRSV-t/cDNA (lane 3), pRSV-T/t-common (lane 4) or the vector plasmid pRSV.3-BglII (lane 5) was transfected into CV-1P cells. Cells were labeled and lysed, and the extracts were immunoprecipitated with anti-T/t-common monoclonal antibody pAB419 as described previously . COS-1 cells (lane 1) served as a positive control for the production of large T and small t. (b) Repression of the human HER-2/neu promoter by the SV40 small t, T/t-common, and large T polypeptides. Two micrograms of pHER498-Luc and 0.3 mg of pRSV-HGH were cotransfected into CV-1P cells with 10 mg of the following plasmids: pRSV.3-BglII (lane 1), pRSV-TEX (lane 2), pRSV-t/cDNA (lane 3), pRSV-T/t-common (lane 4). The luciferase activity obtained by cotransfection of pHER498-Luc and vector plasmid, pRSV.3-BglII, was set to 1.0, and all other activities were expressed relative to this sample. The data represent the average of six independent experiments with standard deviation. (c) Speci®c repression of the HER-2/neu promoter by T/t-common. Two micrograms of pHER498-Luc (lane 1) or pWWP-Luc (lane 2) together with 0.3 mg of pRSV-HGH were cotransfected into SK-OV-3 cells with 10 mg of either pRSV.3-BglII or pRSV-T/t-common. The luciferase activity obtained by cotransfection of pHER498-Luc and pRSV.3-BglII was set to 1.0, and all other activities were expressed relative to this sample. The data represent the average of four independent experiments with standard deviation. (d) Mapping of T/t-common responding region in the HER-2/neu promoter. Upper panel, series deletion constructs of the HER-2/neu promoter-luciferase. Lower panel, repression of various HER-2/neu promoter deletion constructs by T/t-common. Two micrograms of each of the HER-2/neu promoter deletion constructs was cotransfected into CV-1P cells with 10 mg of either pRSV.3-BglII or pRSV-T/t-common. The luciferase activity obtained by cotransfection of pHER498-Luc and pRSV.3-BglII was set to 1.0, and all other activities were expressed relative to this sample. The data represent the average of four independent experiments with standard deviation SK-T/t, SK-NEO, and parental SK-OV-3 cells by Northern blot analysis. As shown in Figure 3a , while the abundance of glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) mRNA, an internal control, was similar in all cell lines, the abundance of HER-2/neu mRNA was much lower in the SK-T/t cells than in the control SK-NEO and parental SK-OV-3 cells. The larger sized transcript seen on the gel is an aberrant form of HER-2/neu mRNA which has been reported previously . This result and the results showing that T/t-common could speci®cally repress the HER-2/neu promoter strongly suggest that T/t-common could inhibit the transcription of the HER-2/neu gene.
Immunoblot analyses were also performed to examine the abundance of the HER-2/neu-encoded p185 protein in these cells. As shown in Figure 3b , while the SK-NEO control cell lines expressed the p185 protein at level comparable to that of the parental SK-OV-3 cells, the SK-T/t cell lines expressed much reduced level of p185. This reduction in p185 level was not due to lower amounts of protein loaded on the gel, because comparable levels of a-tubulin protein were detected on the same blot. It is of interest to note that Ras protein was expressed at similar levels in SK-T/t, SK-NEO and parental SK-OV-3 cells (Figure 3b ). This result indicates that T/t-common speci®cally represses HER-2/neu expression in SK-T/t cells. The heterogeneity of p185 protein has been reported previously (Kiyokawa et al., 1995; Yu et al., 1995) .
To ensure that the decreased synthesis of HER-2/neu mRNA and p185 protein in SK-T/t cell lines was not due to loss or rearrangement of the HER-2/neu gene, Southern blot analysis of the HER-2/neu gene was conducted by using the human HER-2/neu speci®c probes. As shown in Figure 4 , all the four SK-T/t cell lines showed similar band pattern and intensity as the control SK-NEO and parental SK-OV-3 cell lines. This result indicates that the SK-T/t cell lines contain copy number of the HER-2/neu gene similar to that of the control SK-NEO and parental SK-OV-3 cell lines and that the HER-2/neu gene is not rearranged in the SK-T/t cell lines. Taken together, these results demonstrate that the synthesis of T/t-common in the SK-T/t cell lines indeed leads to the inhibition of HER-2/neu expression. In vitro suppression of SK-OV-3 cell transformation by T/t-common Previous studies have shown that inhibition of HER-2/neu expression in the HER-2/neu-overexpressing ovarian carcinoma cell lines can lead to the suppression of transforming ability of these cells (Yu et al., 1993 Zhang et al., 1995; Kao et al., 1998) . To determine whether expression of T/t-common could also suppress the transformed phenotypes of HER-2/ neu-overexpressing SK-OV-3 cells, we ®rst compared the cell morphology of the SK-T/t, SK-NEO, and parental SK-OV-3 cells. While the morphology of the SK-NEO cells looked similar to that of the parental SK-OV-3 cells, the morphology of the SK-T/t cells was markedly dierent. In contrast to the SK-NEO and parental SK-OV-3 cells which exhibited a transformed morphology, all of the four SK-T/t cell lines exhibited a non-transformed,¯attened morphology. The latter cells also grew to lower saturation density than did the SK-NEO and SK-OV-3 cells (data not shown).
We next examined the ability of the SK-T/t cell lines to grow anchorage-independently in soft agar. As shown in Figure 5 , while the control SK-NEO and parental SK-OV-3 cell lines exhibited comparable colony-forming eciency in soft agar, the SK-T/t cell lines showed much reduced colony-forming ability. This result strongly suggests that T/t-common can suppress the transforming ability of the HER-2/neuoverexpressing ovarian carcinoma cells in vitro.
T/t-common acts as a tumor suppressor for HER-2/neuoverexpressing human ovarian carcinoma SK-OV-3 cells A critical test for T/t-common-mediated transformation suppression function in ovarian cancer cells is the ability of T/t-common to suppress tumor formation in vivo. Therefore, tumorigenicity assays were performed in nu/nu mice that were injected s.c. with 3610 6 cells from the SK-T/t, SK-NEO or parental SK-OV-3 cell lines. Mice given injection of the control SK-NEO-1, SK-NEO-2 and parental SK-OV-3 cells formed tumors about 12 ± 16 days after injection, and had huge tumor burdens of 1502+280, 2608+1234 and 1042+ 362 mm 3 , respectively, by 9 weeks postinjection ( Figure  6 ). However, mice injected with the same number of cells from the four SK-T/t cell lines did not form tumors at all even at 9 weeks postinjection. The mice injected with control SK-NEO and parental SK-OV-3 cells generally looked sick and appeared smaller and thinner than those mice injected with SK-T/t cells. These mice started to die at 9 weeks postinjection and no mice survived 14 weeks postinjection. In contrast, mice injected with SK-T/t cells looked healthy and remained alive even at 20 weeks postinjection. These results clearly demonstrate that T/t-common can suppress the tumorigenic potential of the ovarian carcinoma SK-OV-3 cells.
Suppression of the transforming activity of the activated genomic neu by T/t-common
So far we have shown that T/t-common could inhibit HER-2/neu expression and suppress the tumorigenicity of the HER-2/neu-overexpressing SK-OV-3 cells. However, since multiple genetic alterations besides HER-2/neu overexpression could have occurred in SK-OV-3 cells, we were not sure whether suppression of tumorigenicity is a direct result of inhibition of HER-2/neu by T/t-common. To resolve this question, we studied whether T/t-common had the ability to suppress neu-induced transformation directly. The cosmid cNeu-104 encodes the activated genomic rat neu, which has a single point mutation in the transmembrane domain and is driven by 2.2 kb rat neu promoter (Hung et al., 1986; Matin and Hung, 1993; . Upon transfection of cNeu-104 into normal NIH3T3 cells, those cells that express activated neu can be transformed . We cotransfected cNeu-104 with either the Figure 5 Soft-agarose colony formation assay of SK-T/t, SK-NEO, and parental SK-OV-3 cell lines. The numbers of softagarose colonies from each cell line were calculated from six plates and shown with standard deviation Figure 6 Tumor formation by SK-T/t, SK-NEO, and parental SK-OV-3 cell lines. Viable cells (3610 6 ) from indicated cell lines were injected s.c. into the right and left¯anks of homozygous nu/ nu mice. Four mice were injected for each cell line. Tumor volumes were measured at indicated duration (weeks) and shown with standard deviation T/t-common-expressing or the vector plasmid into NIH3T3 cells and assayed for microcolony formation in soft agarose using abortive transformation assay (Stoker, 1968; Rubin et al., 1982) . As shown in Figure 7a , cotransfection of T/t-common signi®cantly suppressed the microcolony-inducing activity of the activated genomic neu. Transfection of T/t-common alone did not have any eect on microcolony formation (Figure 7a, lane 3) . These data demonstrate that T/t-common can suppress genomic neuinduced transformation in NIH3T3 cells. On the contrary, when the pCMVHER2WT plasmid, which contains the HER-2/neu cDNA driven by the immediate early gene promoter of cytomegalovirus (CMV), was contransfected with the T/t-commonexpressing plasmid, no signi®cant inhibition of microcolony formation was observed (Figure 7b ). The fact that T/t-common can only suppress the microcolony-inducing activity of genomic neu driven by its own promoter but not that of HER-2/neu cDNA implies that the T/t-common-mediated transformation suppression may be due to inhibition of neu gene expression but not Neu protein activity by T/t-common in NIH3T3 cells. To study whether T/t-common could suppress cell transformation mediated by other oncogenes, we examined the eect of T/t-common on Ras and Src, which are the downstream signaling molecules of the HER-2/neu protein (Hung and Lau, 1999) . As shown in Figure 7c ,d, the transforming activities of both oncogenic v-H-Ras and v-Src proteins were not aected by T/t-common. These results further demonstrate that T/t-common speci®cally suppresses HER-2/ neu transforming activity through repressing HER-2/ neu expression.
Discussion
Overexpression of HER-2/neu has been demonstrated in many dierent types of human cancers, including ovarian carcinoma, and correlated with poor prognosis. Previous studies showed that adenovirus E1A protein and SV40 large T antigen can suppress the tumorigenicity of HER-2/neu-overexpressing cancer cells by repressing HER-2/neu expression Hung and Lau, 1999 ). Here we report that SV40 T/t-common polypeptide, which contains the Nterminal common domain of SV40 large T and small t antigens, exhibited similar functions as E1A and large T, that is, it could repress HER-2/neu expression ( Figure 3 ) and suppress the tumorigenic potential of the HER-2/neu-overexpressing ovarian carcinoma cells ( Figures 5 and Figure 6 ). Moreover, we also found that T/t-common could speci®cally suppress the transforming activity of the activated genomic neu, presumably through repressing neu expression. Taken together, these data suggest that T/t-common may function as a transformation suppressor of the HER-2/neu oncogene.
Previous studies have clearly demonstrated that repression of HER-2/neu expression leads to suppression of tumorigenic potential of HER-2/neu-overexpressing cancer cells. In this study, we also found that expression of T/t-common in the HER-2/neuoverexpressing ovarian carcinoma SK-OV-3 cells led to a reduced HER-2/neu expression and concomitantly suppressed the tumorigenicity. The ability of T/tcommon to suppress the tumorigenicity of SK-OV-3 cells is, at least partially, derived from its ability to inhibit HER-2/neu expression. This conclusion is supported by the following observations: (i) T/tcommon could directly suppress the transforming activity of genomic neu driven by its own promoter, but not that of HER-2/neu cDNA driven by the CMV immediate early gene promoter ( Figure 7a,b) ; (ii) T/tcommon could not suppress the transforming activities of v-H-Ras and v-Src proteins, which are the downstream signaling molecules of the HER-2/neu protein (Figure 7c,d) . Whether suppression of tumorigenicity by T/t-common was mediated solely through blocking HER-2/neu expression is not clear, as SK-OV-3 cells presumably contain multiple genetic defects besides HER-2/neu overexpression. T/t-common may suppress the tumorigenicity of SK-OV-3 cells through correcting these other defects besides HER-2/neu overexpression. In this respect, it is worth noting that T/t-common is a potent transcriptional repressor for a variety of promoters/enhancers . In addition, recent studies have shown that T/t-common contains a motif similar to the J domain, a conserved sequence found in the DNAJ family of molecular chaperones (Brodsky and Pipas, 1998) . It is possible that these activities of T/t-common also contribute to T/tcommon's tumor suppressing function.
What is the mechanism underlying repression of the HER-2/neu gene by T/t-common? Chen and Hung showed that p300, a transcriptional coactivator (Eckner et al., 1994; Janknecht and Hunter, 1996) , plays an important role in the transcriptional activation of HER-2/neu and serves as a target for the E1A-mediated repression of HER-2/neu . E1A is a potent transcriptional repressor that can repress a variety of promoters/enhancers. It is generally believed that the repressing function of E1A is derived from its ability to interact with and consequently inactivate the transcriptional coactivator p300 (Wang et al., 1993; Eckner et al., 1994; Janknecht and Hunter, 1996) . Several evidences suggest that T/tcommon, like E1A, may also target p300 and thus inhibit p300-dependent transcription. Firstly, T/tcommon expresses a biological activity equivalent to the N-terminal non-conserved domain and the conserved domain 1 of E1A (Yaciuk et al., 1991) . Coincidentally, these two domains of E1A have been shown to be responsible for E1A repression of many genes, including HER-2/neu , and harbor the p300 binding site (Wang et al., 1993) . Secondly, the N-terminal region of T/t-common reveals some sequence homology to that of E1A involving the binding of p300 (Dyson et al., 1989) . Thirdly, it has been reported that the N-terminal region of large T (including T/t-common region) inhibits p53-mediated transcription (Rushton et al., 1997) and overcomes wild-type p53-mediated cell cycle arrest (Quartin et al., 1994) . Since p300 has been shown to be a transcriptional coactivator of p53 and involved in p53-mediated growth control (Lill et al., 1997; Avantaggiati et al., 1997) , the above observations suggest that the Nterminal region of large T interacts with and inactivates p300 and consequently disrupts functions mediated by p53 (Rushton et al., 1997) . Fourthly, we have found that small t and T/t-common could inhibit the coactivating activity of wild-type p300 but not that of mutant p300 that sustains a deletion at the E1A-binding domain (data not shown). Moreover, by using mammalian two-hybrid assays, we have demonstrated that there was a protein ± protein interaction between small t and p300 (data not shown). When this evidence is combined with the report by Chen and Hung that p300 is a coactivator for the transcription of the HER-2/neu gene, we suspect that T/t-common may repress HER-2/neu transcription by targeting p300. We have mapped the T/t-common-responsive element within the HER-2/neu promoter to a region located between 781 and +30 relative to the major transcription start site of the HER-2/neu gene (Figure 1d ). It will be of interest to study whether p300 interacts with this region of the HER-2/neu promoter.
It has been reported previously that SV40 large T antigen represses neu expression and thereby suppresses the neu-mediated transformation (Matin and Hung, 1993) . While our studies were in progress, Kao et al. (1998) reported that a deletion mutant of large T, T178, which contains only N-terminal 178 amino acids of large T, also down-regulates HER-2/neu expression and suppresses the tumorigenicity of the HER-2/neu-overexpressing ovarian carcinoma cells. These results suggest that large T and its derivative T178 may be considered as targeting agents for the treatment of HER-2/neu-overexpressing cancers Kao et al., 1998) . However, a serious concern exists as large T is also a potent viral oncoprotein which can fully transform cells in culture and induce tumors in nude and transgenic mice (Tooze, 1981; Srinivasan et al., 1989; SaÈ enz Robles et al., 1994; Tevethia et al., 1997) . Moreover, a mutant large T containing the Nterminal 121 or 127 amino acids is sucient to transform some cells and induces choroid plexus tumors and pancreatic acinar carcinoma in transgenic mice (Srinivasan et al., 1989 SaÈ enz Robles et al., 1994 Tevethia et al., 1997) . Therefore, both large T and T178 would not be safe therapeutic agents for cancer treatment. In contrast, T/t-common alone lacks transforming activity (Montano et al., 1990) . While a truncated large T, dl1137, which contains the wild-type N-terminal 121 amino acids of large T, is capable of inducing choroid plexus tumors in transgenic mice, a mutant dl1137 containing a mutation at residue 107 loses its ability to interact with pRB and does not induce tumors (SaÈ enz Robles et al., 1994) . This latter result also strongly suggests that T/t-common that contains only the N-terminal 82 amino acids of large T could not induce tumors in an animal. Taking these arguments together with our results, we believe that T/ t-common has the potential to be developed into a safer therapeutic agent for the treatment of HER-2/ neu-overexpressing cancers. Experiments aimed at testing this possibility are in progress.
Materials and methods

Cell lines and culture
The SK-OV-3 human ovarian carcinoma cell line was purchased from the American Type Culture Collection. The SK-OV-3 cells were grown in the Dulbecco's modi®ed Eagle medium (DMEM)/F12 nutrient mixture (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) in 5% CO 2 . The SK-OV-3 derivative cells (SK-T/t-1, SK-T/t-2, SK-T/t-3, SK-T/t-4, SK-NEO-1 and SK-NEO-2) were grown under the same conditions, except that G418 (200 mg/ml) was added to the culture media. The monkey kidney CV-1P cells, 293 cells and NIH3T3 cells were cultured in DMEM (Gibco) supplemented with 10% FBS in 5% CO 2 .
Plasmids
The plasmid pHER498-Luc was constructed as follows. The promoter region (nucleotide 7498 to +30 relative to the major transcription start site) of human HER-2/neu (Tal et al., 1987) was ampli®ed by PCR with a pair of primers (sense: 5'-GATAGGATCCGGGGGTCCTGGAAGCC, and antisense: 5'-GGGCAGATCTGGTTTCTCCGGTCCCAATG-GA) using genomic DNA prepared from normal human peripheral blood monocytes. The ampli®ed DNA fragment was phosphorylated by T4 polynucleotide kinase and then ligated into the SmaI site of pGL3-Basic (Promega, Madison, WI, USA) to generate pHER498-Luc. The sequence of this promoter-containing insert was con®rmed by DNA sequencing. The series HER-2/neu promoter deletion constructs were generated by PCR with a common antisense primer (5'-GGGCAGATCTGGTTTCTCCGGTCCCAATGGA) and distinct sense primers (5'-AAACAAATAGGCTTGGG for pHER398-Luc; 5'-AATTTATCCCGGACTCC for pHER300 -Luc; 5'-AGGCGTCCCGGCGCTAGG for pHER205-Luc; 5'-TTGCTCCCAATCACAGG for pHER81-Luc) using pHER498-Luc as a template. The ampli®ed DNA fragments were phosphorylated by T4 polynucleotide kinase and then ligated into the SmaI site of pGL3-Basic to generate pHER398-Luc, pHER300-Luc, pHER205-Luc and pHER81-Luc, respectively. Plasmids pRSV.3-BglII, pRSV-t/ cDNA, pRSV-T/t-common, pRSV-TEX, pRSV-HGH, pWWP-Luc, pZIP-v-H-ras, and the cosmid cNeu-104 have been described previously (Matin and Hung, 1993; El-Deiry et al., 1993; Wang et al., 1994; Liu et al., 1995) . Plasmid pCMVHER2WT, which contains a HER-2/neu cDNA driven by the CMV immediate early gene promoter, was kindly provided by Dr Mien-Chie Hung. The plasmid pKR5 v-src (Tsai et al., 2000) , which contains v-src driven by the CMV immediate early gene promoter, was a gift from Dr RueyHwa Chen. The pcDNA3 plasmid, which is a backbone vector for pCMVHER2WT, and the pRc/CMV plasmid were purchased from Invitrogen (Carlsbad, CA, USA).
Transient transfection; luciferase activity and human growth hormone (HGH) assays DNA transfection was performed as described previously . CV-1P or SK-OV-3 cells were seeded in 35 mm-diameter plates 24 h before transfection. Cells were transfected at 70% con¯uency by the calcium phosphate coprecipitation technique (Sambrook et al., 1989) ; 0.3 mg of pRSV-HGH, a plasmid which contains a Rous sarcoma virus long terminal repeat-driven HGH gene, was also cotransfected as an internal control for transfection eciency. The cells were exposed to the transfection precipitate for 8 ± 10 h, washed twice with fresh medium, and refed with fresh medium containing 10% FBS. After 10 ± 12 h, 100 ml of culture medium was taken for the HGH assay (It is important to take HGH samples within 10 to 12 h after transfection, because small t and T/t-common modestly aected the Rous sarcoma virus long terminal repeat promoter after long incubation). Cells were incubated for an additional 36 h before harvesting for luciferase activity assay.
HGH levels in the culture medium were measured with a solid-phase, two-site radioimmunoassay kit under the conditions recommended by the manufacturer (Nichols Institute Diagnostics, San Juan Capistrano, CA, USA). The HGH values, which represent the eciency of transfection, would be used later to calibrate the amount of cell lysates used in the luciferase activity assays. Luciferase activity assays were preformed as described previously (Hong et al., 1997) . Light emission was measured by using TopCount, a microplate scintillation and luminescence counter (Packard Instrument, Meriden, CT, USA).
Establishment of T/t-common stable transfectants
SK-OV-3 cells were transfected with 6 mg of either pRSV.3-BglII or pRSV-T/t-common together with 0.5 mg of pRc/ CMV, which contains a neomycin resistance gene, by calcium phosphate coprecipitation method as described above. The cells were trypsinized and then split at a 1 : 10 ratio 46 h after transfection. After 4 ± 6 weeks selection using medium containing 800 mg/ml of G418, individual G418-resistant colonies were cloned. For the selection of T/t-commonexpressing stable clones, cells from individual G418-resistant clones were checked for the synthesis of T/t-common mRNA using RT ± PCR. A pair of primers (sense: 5'-CCGGAATT-CATGGATAAAGTTTTAAAC, and antisense: 5'-CCGGAATTCTTACTCAGTTGCATCCCAGAA) which encompass the T/t-common coding sequence were used in the PCR. Those clones which produced T/t-common mRNA were further analysed by immunoprecipitation using anti-T/t-common monoclonal antibody pAB419 as described previously . The immunoprecipitates were electrophoresed in a 15% sodium dodecyl sulfate (SDS)-polyacrylamide gel, which was then autoradiographed.
Northern blot analysis
Total cellular RNA was extracted with a guanidinium thiocyanate-phenol mixture as described previously (Chomczynski and Sacchi, 1987) . Northern blot analyses were performed as described previously (Sambrook et al., 1989) . Brie¯y, 10 mg of RNA from each sample was denatured with glyoxal and dimethyl sulfoxide, electrophoresed through a 1.2% agarose gel submerged in 10 mM sodium phosphate (pH 7.0), and then transferred to the Hybond-N membrane (Amersham, Arlington Heights, IL, USA). RNAs were crosslinked to the membranes by UV irradiation. The blotted RNAs were then hybridized at 428C with random-primed 32 Plabeled probes prepared by using Rediprime Random primer labeling kit (Amersham). For the detection of HER-2/neu mRNA, the probes used were two AccI fragments (0.8 and 1.2 kb) isolated from the plasmid pCER204 (Yamamoto et al., 1986) . For the detection of GAPDH mRNA, a full-length GAPDH cDNA was used as probe (Fort et al., 1985) . The blots were washed twice at 258C for 30 min with cold wash buer (26SSC and 0.2% SDS; 16SSC=150 mM NaCl and 15 mM sodium citrate) and once at 558C for 10 min with hot wash buer (0.16SSC and 0.2% SDS). The dried blots were then exposed to Kodak BioMax X-ray ®lm for 30 h.
Western blot analysis
Western blot analyses were performed as described previously (Harlow and Lane, 1988) . Cells were lysed in the sample buer [130 mM Tris-HCl (pH 6.8), 2% SDS, and 10% glycerol]. Protein content was determined against a standardized control using the Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Equivalent amounts of extract protein (50 mg) were resolved in 8% SDS-polyacrylamide gels, and electroblotted onto the Immobilon-P transfer membrane (Millipore, Bedford, MA, USA). For detection of the HER-2/neu-encoded p185 protein, Ras protein, and the internal control a-tubulin protein, the blot was incubated with three primary antibodies [anti-p185 neu monoclonal antibody c-neu-Ab-3 (1 : 3000 dilution; Oncogene Science, Cambridge, MA, USA); anti-human Ras monoclonal antibody (1 : 500 dilution; Transduction Laboratories, Lexington, KY, USA) and anti-a-tubulin monoclonal antibody (1 : 1000 dilution; Zymed Laboratories, San Francisco, CA, USA], followed by incubating it with horseradish peroxidaseconjugated goat anti-mouse IgG antibody (1 : 2000 dilution; Amersham). The protein bands were then visualized with enhanced chemiluminescence Western blotting detection reagents (Amersham).
Southern blot analysis
Southern blot analyses were performed as described (Sambrook et al., 1989) . Genomic DNAs (8 mg) extracted from cultured cells were digested overnight at 378C with a threefold excess of BamHI. The digested DNAs were then resolved by electrophoresis on a 0.8% agarose gel and transferred to the Hybond-N membrane (Amersham) using 206SSC. The blotted DNAs were then hybridized at 428C with a combination of 32 P-labeled human HER-2/neu speci®c probes. The probes were prepared by labeling two AccI fragments (0.8 and 1.2 kb) and one SmaI fragment (0.3 kb) isolated from the plasmid pCER204 (Yamamoto et al., 1986 ) with 32 P using Rediprime Random primer labeling kit (Amersham). The blots were washed twice at 258C for 30 min with cold wash buer (26SSC and 0.2% SDS) and once at 558C for 10 min with hot wash buer (0.16SSC and 0.2% SDS). The dried blots were then exposed to Kodak BioMax X-ray ®lm for 30 h.
Colony formation in soft agarose
5610
3 cells were seeded in 35 mm plates in culture medium containing 0.35% agarose overlying a 0.7% agarose layer. After 4 weeks incubation, colonies were stained with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; 5 mg/ml; Sigma, St Louis, MO, USA) at 378C for 2 h. Colonies larger than 100 mm were counted for each plate. Experiments were repeated three times with duplicate plates for each cell line.
Tumorigenicity assay
3610
6 viable log-phase cells in 0.3 ml of phosphate-buered saline (140 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , and 1.8 mM KH 2 PO 4 ) were injected s.c. into both the right and left¯anks of the 4-to 5-week-old pathogen-free BALB/ cAnN-nu/nu athymic mice under aseptic conditions. Tumor volumes were estimated as the product of three-dimensional caliper measurements (longest surface length and width; tumor thickness). The growth of tumors was monitored weekly for 9 weeks.
Abortive transformation assay
The cosmid cNeu-104, pCMVHER2WT, pZIP-v-H-ras, or pKR5 v-src (1.5 mg) together with a drug selection plasmid pCMV-neo (1.5 mg) were cotransfected into NIH3T3 cells (grown in 60 mm plates) with 15 mg of either a T/t-commonexpressing plasmid (pRSV-T/t-common) or a vector plasmid (pRSV.3-BglII). A similar number of cells was transfected in each case. Cells were trypsinized and split 48 h after transfection. For each transfected plate, 40% of the cells were seeded in the soft-agarose plate (see above for experimental detail) for microcolony formation assay and 20% of the cells were seeded in the G418-containing (500 mg/ ml) plate for selection of G418-resistant colonies to measure transfection eciency. Microcolonies larger than 35 mm in diameter (about eight cells) were counted for each plate 12 days after seeding. G418-resistant colonies were also counted 12 days after seeding. The number of microcolonies induced by each transfection was calculated by subtracting the number of microcolonies formed spontaneously by NIH3T3 cells and then corrected for transfection eciency as indicated by the number of G418-resistant colonies.
